Preclinical evaluation of the effects on the gastrointestinal tract of the antineoplastic drug vincristine repeatedly administered to rats

dc.contributor.authorLópez Gómez, Laura
dc.contributor.authorDíaz Ruano, Susana
dc.contributor.authorGirón, Rocío
dc.contributor.authorLópez Pérez, Esther
dc.contributor.authorVera, Gema
dc.contributor.authorHerradón, Esperanza
dc.contributor.authorLópez Miranda, Visitación
dc.contributor.authorNurgali, Kulmira
dc.contributor.authorMartín-Fontelles, Isabel
dc.contributor.authorUranga, Jose Antonio
dc.contributor.authorAbalo, Raquel
dc.date.accessioned2024-02-07T10:50:53Z
dc.date.available2024-02-07T10:50:53Z
dc.date.issued2018-05-25
dc.description.abstractBackground: Vincristine is a commonly used chemotherapeutic agent. It is associated with undesirable digestive side effects. However, the impact of vincristine on gastrointestinal structure and motility or its long-term effects have not been deeply studied in animal models. This could be useful in order to develop therapeutic or preventive strategies for cancer patients. The aim of this study was to analyze such effects. Methods: Rats received saline or vincristine (0.1 mg kg−1, ip) daily for 10 days. Evaluations were performed during treatment and 2-6 weeks after. Somatic mechano-sensitivity was assessed using von Frey hairs. Gastrointestinal motor function was studied by means of radiographic still images and colonic propulsion of fecal pellets using fluoroscopy videos. Histological assessment of the gut morphology and immunohistochemistry for HuC/D and nNOS were performed in whole-mount myenteric plexus preparations. Key Results: Peripheral sensitivity was increased in animals treated with vincristine and did not subside 2 weeks after treatment finalization. Vincristine treatment inhibited gastrointestinal motility although this was recovered to normal values with time. Damage in the digestive wall after vincristine treatment was greater in the ileum than in the colon. Villi shortening (in ileum) and large inflammatory nodules still remained 2 weeks after treatment finalization. Finally, the proportion of nNOS-immunoreactivees
dc.identifier.citationNeurogastroenterology & Motility. 2018;e13399.es
dc.identifier.doi10.1111/nmo.13399es
dc.identifier.issn1365-2982
dc.identifier.urihttps://hdl.handle.net/10115/29866
dc.language.isoenges
dc.publisherJohn Wiley & Sons Ltdes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectfluoroscopy, gastrointestinal motility, immunohistochemistry, neuropathy, vincristinees
dc.titlePreclinical evaluation of the effects on the gastrointestinal tract of the antineoplastic drug vincristine repeatedly administered to ratses
dc.typeinfo:eu-repo/semantics/articlees

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
López et al NGM 2018.pdf
Tamaño:
2.55 MB
Formato:
Adobe Portable Document Format
Descripción:

Bloque de licencias

Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.67 KB
Formato:
Item-specific license agreed upon to submission
Descripción: